704P - Results from phase I study of the oncolytic viral immunotherapy agent Canerpaturev (C-REV) in combination with gemcitabine plus nab-paclitaxel as first-line treatment of unresectable pancreatic cancer

Y Hashimoto,S Hijioka,Y Hirooka,E Ohno,T Ioka,S Kobayashi,T Okusaka,Y Maruki,J Yashika,R Ashida,J Furuse,M Ikeda,H Kasuya,M Tanaka,M Ueno

doi:10.1093/annonc/mdz247.031

704P - Results from phase I study of the oncolytic viral immunotherapy agent Canerpaturev (C-REV) in combination with gemcitabine plus nab-paclitaxel as first-line treatment of unresectable pancreatic cancer

Y Hashimoto, S Hijioka + Show 13 more

Open Access

https://doi.org/10.1093/annonc/mdz247.031

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Oct 1, 2019
Citations: 2	License type: publisher-specific-oa

Affiliation: National Cancer Center Hospital East, Fujita Health University, Nagoya University Hospital, Osaka International Cancer Institute, Kanagawa Cancer Center, Kyorin University Hospital, Takara (Japan)

#Research Grant #Gemcitabine + Nab-paclitaxel + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

704P - Results from phase I study of the oncolytic viral immunotherapy agent Canerpaturev (C-REV) in combination with gemcitabine plus nab-paclitaxel as first-line treatment of unresectable pancreatic cancer

Full Text